Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health)

Benign Prostatic Hyperplasia (BPH) and Male Urology

$1.0B Combined BSC+AMS urology business at deal close (~$1B annual sales)

Disease Overview

Benign prostatic hyperplasia, male stress urinary incontinence, and erectile dysfunction collectively affect a majority of aging men, with histological BPH present in 50-80% of men over 60. Device-based therapies (laser ablation, slings, penile prostheses) treat moderate-to-severe symptoms refractory to medical management.

Competitive Landscape

The 2015 Boston Scientific acquisition of Endo's American Medical Systems Men's Health and Prostate Health business — $1.6B upfront plus a $50M sales-based earn-out — was a pure device transaction that immediately doubled BSC's urology revenue base to roughly $1B in combined sales. The acquired franchise was anchored by GreenLight XPS/HPS photoselective vaporization laser systems for BPH (competing with Teleflex's UroLift system, NeoTract's UroLift later acquired by Teleflex in 2017 for $1.1B, and Boston Scientific's own Rezum water vapor therapy via Olympus and prostate enucleation systems), the AMS 800 Urinary Control System for male stress urinary incontinence (effectively the gold-standard artificial urinary sphincter with limited competition), and the AMS 700 Inflatable Penile Prosthesis for erectile dysfunction (competing with Coloplast's Titan IPP). Endo divested the unit to refocus on specialty pharma (Vasostrict, Xiaflex) and reduce mesh-related litigation exposure that had already cost the company billions. For BSC the deal was the cornerstone of building a global urology franchise that subsequently absorbed BTG (2019) and Lumenis Surgical (2021).